Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma” by Giovanni Barosi and Robert Peter Gale

Sarah A Holstein, Vera J. Suman, Philip L. McCarthy

Research output: Contribution to journalArticle

Original languageEnglish (US)
JournalLeukemia
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Autografts
Standard of Care
Multiple Myeloma
lenalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{85de218534bb4b45b95a7f13be941b0c,
title = "Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma” by Giovanni Barosi and Robert Peter Gale",
author = "Holstein, {Sarah A} and Suman, {Vera J.} and McCarthy, {Philip L.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41375-018-0359-7",
language = "English (US)",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma” by Giovanni Barosi and Robert Peter Gale

AU - Holstein, Sarah A

AU - Suman, Vera J.

AU - McCarthy, Philip L.

PY - 2019/1/1

Y1 - 2019/1/1

UR - http://www.scopus.com/inward/record.url?scp=85059890615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059890615&partnerID=8YFLogxK

U2 - 10.1038/s41375-018-0359-7

DO - 10.1038/s41375-018-0359-7

M3 - Article

JO - Leukemia

JF - Leukemia

SN - 0887-6924

ER -